Erytech Pharma jumps on cancer study data publication

Phaxiam Therapeutics SA

07/04/2022 10:06

** U.S.-listed shares of French drug developer  ERYP.O  rise
~54% to $2.43 premarket
    ** On Wednesday after market, co said positive top-line data
from mid-stage study of experimental therapy eryaspase in acute
lymphoblastic leukemia (ALL) was published in British Journal of
Haematology  urn:newsml:reuters.com:*:nGNX666tjD
    ** ALL is a cancer of blood and bone marrow - most common
type of cancer in children in U.S. and Europe
    ** Trial was conducted at 21 clinical sites in Europe and
enrolled 55 ALL patients who had experienced hypersensitivity
reactions to prior treatment with pegylated asparaginase 
    ** Main goals of trial were asparaginase enzyme activity and
safety, both were met - ERYP
    ** Up to Wednesday's close, stock had fallen ~33% YTD

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))